Zymeworks (ZYME) news
Recent news
Zymeworks, Inc.: H.C. Wainwright raises target price to $55 from $51
Zymeworks, Inc. (NASDAQ: ZYME) has seen recent analyst activity that reflects growing confidence in its therapeutic pipeline and financial performance. H.C. Wainwright recently raised its price target for Zymeworks to $32 from $26, maintaining a "Buy" rating. This adjustment follows positive…
AInvest Wire · 5d agoTheravance Biopharma acquisition by Zymeworks to close in 2H
Zymeworks Inc. (Nasdaq: ZYME) has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (Nasdaq: TBPH) for $17.00 per share in cash, representing an equity value of approximately $929 million. The transaction is expected to close in the second half of 2026, subject to customary…
AInvest Wire · Aug 10, 2026Zymeworks Q2 EPS USD -0.62 vs. IBES estimate USD -0.46
AInvest Wire · Aug 6, 2026HBM Healthcare Investments delivers strong quarterly performance, expects profit of CHF 238 million
HBM Healthcare Investments AG reported a strong quarterly performance, with expectations of a profit of CHF 238 million for the period. This follows the company’s overall positive performance in its 25th financial year, which concluded with a total profit of CHF 272 million . The net asset value…
AInvest Wire · Jul 1, 2026Zymeworks, Inc.: Wells Fargo raises target price to $37 from $34
AInvest Wire · Jun 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.